SHINPOONG PHARMACEUTICAL CO.,LTD
Financials
Valuation Metrics
SHINPOONG PHARMACEUTICAL CO.,LTD's Market Cap is ₩5100B. At end of 2025 it was ₩7827B. Ranked #439 of 2,414 in KR market (top 18%), #287 of 781 on KOSPI (top 37%), #47 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 20%) by Market Cap.
Investment Metrics(as of 2026-10-15)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 510.03B KRW | KR#439/2,414 Sec#47/231 |
| Revenue | 239.07B KRW | KR#941/2,414 Sec#53/231 |
| Net Income | -746.5M KRW | KR—/2,414 Sec—/231 |
| Total Assets | 366.50B KRW | KR#923/2,414 Sec#58/231 |
| Net Assets | 278.04B KRW | KR#754/2,414 Sec#49/231 |
| Employees | 832 | KR#299/2,414 Sec#24/231 |
| Value | ||
| P/B | 1.83x | KR#1,915/2,414 Sec#141/231 |
| P/S | 2.13x | KR#1,872/2,414 Sec#109/231 |
| EV/EBITDA | 191.09x | KR#1,530/2,414 Sec#104/231 |
| FCF Yield | 2.70% | KR#1,018/2,414 Sec#64/231 |
| Profitability | ||
| ROE | -0.27% | KR#1,566/2,414 Sec#108/231 |
| ROA | -0.20% | KR#1,576/2,414 Sec#108/231 |
| Op. Margin | 1.13% | KR#1,491/2,414 Sec#104/231 |
| Revenue Growth | 6.21% | KR#1,121/2,414 Sec#109/231 |
| Financial Health | ||
| Debt Ratio | 31.82% | KR#624/2,414 Sec#73/231 |
| Total Debt | 52.40B KRW | KR#987/2,414 Sec#67/231 |
| FCF | 13.78B KRW | KR#623/2,414 Sec#34/231 |
| Cash | 48.09B KRW | KR#754/2,414 Sec#45/231 |
| Current Ratio | 2.86x | KR#593/2,414 Sec#78/231 |
| Net Debt/EBITDA | 1.60x | KR#799/2,414 Sec#55/231 |
| Dividend | ||
| Div. Growth | 0.00% | KR—/2,414 Sec—/231 |
| Performance | ||
| 1Y Return | -29.23% | KR#1,448/2,414 Sec#113/231 |
| 1M Return | -6.98% | KR#1,242/2,414 Sec#117/231 |
| From 52W High | -42.14% | KR#873/2,414 Sec#62/231 |
| 1Y MDD | -54.05% | KR#1,159/2,414 Sec#95/231 |
| Trading | ||
| Volume | 261,101 shares | KR#469/2,414 Sec#40/231 |
| Trading Value | 2.39B KRW | KR#540/2,414 Sec#51/231 |
| Foreign Own. | 4.35% | KR#973/2,414 Sec#87/231 |
| Per Share | ||
| EPS | -13 KRW | KR—/2,414 Sec—/231 |
| BPS | 5,015 KRW | KR#1,497/2,414 Sec#106/231 |
Company Info
Established in 1962 and listed on the Korea Exchange in 1990, the company is a mid-sized pharmaceutical enterprise primarily focusing on the manufacturing and sale of finished pharmaceutical products and active pharmaceutical ingredients. It operates six subsidiaries for overseas market entry in countries like Vietnam, Philippines, Myanmar, and the United States. The company concentrates its mid-to-long-term capabilities on global new drug development and secures domestic market competitiveness by launching improved new drugs and first generics, and fostering highly profitable items into mega-products.